Repros Therapeutics — Investor Presentation (June 2016)
20 slides from Repros Therapeutics's investor presentation, Jun 7, 2016
Slide 1: Repros Therapeutics
Repros Therapeutics Development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertaint
Slide 3: Proellex: Addressing significant unmet female reproductive disorders
Proellex Addressing significant unmet female reproductive disorders
Slide 4: Proellex Evolution of Lead Compound
PROELLEX EVOLUTION OF LEAD COMPOUND O CH 3 O OMe N OAc CH 3 H 3 C 44 Analogues Synthesized to Date O CH 3 N CH 3 H 3 C C OH C CH3 O CH 3 OH 3 C N OAc CH 3 H 3 C CDB - 2477 (RU486) CDB - 2914 Ulipristal Acetate CDB - 4124
Slide 5: An Effective Dose of Proellex Stops Menstruation in Majority of Women
An Effective Dose of Proellex Stops Menstruation in Majority of Women Induction of amenorrhea relieves key symptoms of uterine fibroids and endometriosis 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea Mimics early
Slide 6: Impact of Proellex Treatment of Uterine Fibroids
Impact of Proellex Treatment of Uterine Fibroids 58.3 46.2 80.0 80.0 0.0 18.2 0 10 20 30 40 50 60 70 80 90 6 mg Vaginal 12 mg Vaginal 6 mg Oral 12 mg Oral Placebo Vaginal Placebo Oral Subjects with Amenorrhea (%) - 27.3 - 13.4 - 13.5 - 40.0 3.6 3.5 -45 -40 -35 -30 -25 -20 -15 -10 -5 0 5 10 6 mg Vagi
Slide 7: Interim ZPE-202 Assessment: Menstrual Pain and Pain Pills
0 2 4 6 8 10 12 14 Baseline 18 weeks Days Mean Sum of Daily Menstrual Pain (28 days) Placebo Proellex 0 5 10 15 20 25 30 35 Baseline 18 Weeks Number of Pain Pills Taken Total Number of Pain Pills (28 days) Placebo Proellex Interim ZPE - 202 Assessment 18 Weeks of Treatment Placebo n=6, Proellex n=15
Slide 8: Proellex Clinical Goals
Proellex Clinical Goals • Confirm Phase 3 requirements with FDA • Uterine Fibroids: Fourth Quarter 2016 • Endometriosis: First Quarter 2017 • Completed Proellex NDA components • Pre - clinical complete (including 2 carcinogenicity studies) • Manufacturing complete (API sourced, stable final drug pro
Slide 9: Enclomiphene: Rational treatment for secondary hypogonadism
Enclomiphene Rational treatment for secondary hypogonadism
Slide 10: Enclomiphene Development Status
Enclomiphene Development Status • Central EU filing ongoing – Anticipated marketing authorization Q4 - ’17 – Treatment for secondary hypogonadism • FDA Complete Response to NDA – Must provide evidence of clinical benefit • US Phase 2 “Proof of Concept” to evaluate clinical benefit – Type C meeting w
Slide 11: Prescription Claims for Testosterone Products
Prescription Claims for Testosterone Products Nguyen et al N Eng J Med 2015 73% 9% 3%
Slide 12: Categorizing Gonadal Status by Testosterone and LH
0 20 40 60 80 LH (U/L) 0 10 20 30 40 50 Total Testosterone (nmol/L) Primary Hypogonadism Low T, high LH n=52 (1.7%) n = 3219 40 – 80 yr Categorizing Gonadal Status by Testosterone and LH Eugonadal Normal T and LH Compensated ‘Hypogonadism ’ Normal T, high LH Secondary Hypogonadism Low T, normal/low
Slide 13: Risk Factors Secondary vs Primary Hypogonadism
Risk Factors Secondary vs Primary Hypogonadism Age ( yrs ) BMI ≥ 25 - <30 kg/m 2 BMI ≥ 30 kg/m 2 Smoking ( current) Alcohol ( frequent) Co - morbidity ( ≥ 1) 0 5 10 15 *** *** * Adjusted Relative Risk Ratio Secondary Obesity Related Hypogonadism EMAS Tajar, JCEM 2010 0 5 10 15 *** Hypogonadism of Ag
Slide 14: Size of Overweight and Obese US Population
Size of Overweight and Obese US Population It is more than a sex issue 83,740,000 Males Age 20 - 60 58,620,000 Overweight or Obese 28,470,000 Metabolic Syndrome 1,700,000 Symptomatic (libido, etc.) Overweight or Obese Estimates based on CDC, EMAS and Sponsor Data
Slide 15: Exogenous Testosterone for Secondary Hypogonadism
Exogenous Testosterone for Secondary Hypogonadism 15 Hypothalamus Pituitary Androgen Effects Fertility Estradiol (E 2 ) DHT GnRH LH FSH + - T + Testis Leydig cells Sertoli cells Testosterone ( T) Spermatogenes is T T Exogenous Testosterone Suppresses the HPG Axis
Slide 16: Obesity Related Hypogonadism is a Reversible Disorder
Camacho et al. European Journal of Endocrinology 2013 Obesity Related Hypogonadism is a Reversible Disorder Treatment with Exogenous T “May require lifelong therapy” (Bayer abstract quote) (a) Total testosterone ( nmol I - 1 ) in hypogonadal men with continuous (n=115) and interrupted (n=147) testos
Slide 17: How Enclomiphene Works
How Enclomiphene Works Enclomiphene blocks estrogen at the level of the H - P axis increasing LH levels which in turn increases endogenous production of T 0 1 2 3 4 5 6 7 Enclomiphene LH Androgel LH Median LH ( mIU /mL) Impact on LH in 16 Wk Study ZA - 304 Baseline End of Study 0 50 100 150 200 250
Slide 18: Proof of Concept Diet & Exercise Study in Obese Hypogonadal Men
Phase 2 Proof of Concept “Diet & Exercise” Study in Obese Hypogonadal Men - Baseline Findings Screen 98 to enroll 50 15 Month Study • Enrollment (n=50 in 5 weeks @ 5 sites) • Demographics ( stdev ) – Age: 43.3 (9.2) – BMI: 36.8 (3.2) – Waist: 46.9” (4.1) – % Body Fat: 38.1 (5.2) • Hormonal Status –
Slide 19: Interim Month Data
Interim 3 Month Data ZA - 205 31 32 33 34 35 36 37 38 39 Bl 3 mo 6 mo 9 mo 12 mo 15mo BMI BMI Over Time 12.5 mg 25 mg pbo 0 50 100 150 200 250 300 350 400 450 Scr BL 3 mo 6 mo 9 mo 12 mo 15 mo Morning T (ng/ dL ) Morning T Over Time 12.5 mg 25 mg pbo Commercial diet ends at 6 months. Personal traine
Slide 20: Repros Late Stage Assets
Repros Late Stage Assets Repros seeking regional or global development/commercialization partners
Repros Therapeutics — Investor Presentation (June 2016) on 6ix